Table 3 Published trials of directly... | American Society of Hematology

Table 3

Published trials of directly selected donor-derived VSTs

Virus	T-cell activator or capture	Patients	Antiviral effects	GVHD	Reference
IFN−γ capture
EBV	Peptides derived from 11 EBV antigens	6	CR in 3 of 6 patients	None	49
EBV	EBNA-1 protein	10	CR in 7 of 10 patients	One grade 2 skin GVHD	23
CMV	CMV-pp65 protein	18	PR or complete response in 15 of 18	One possible GVHD	22
CMV	Recombinant pp65 or pool of overlapping CMV-pp65 peptides	18	Eleven of 11 cleared disease	Five grade 1; 2 grade 2; 1 grade 3 acute GVHD	38
CMV	Two CMV-pp65 peptides	6	Six of 6 cleared CMV viremia	None	50
ADV	ADV antigen type C	9	Five of 6 evaluable had complete response or PR	One exacerbation of GVHD	37
ADV	ADV hexon protein	30	Twenty-one of 30 responded	Two with grade 1 GVHD	51
Multimer selection
CMV	Peptides from CMV-pp65 or IE-1	9	Eight of 9 cleared CMV	Two with grade 1 or 2 GVHD	52
CMV	Peptides from CMV-pp65	2	Two of 2 CR	None	53
CMV	NLV-containing HLA-A02 pentamers	2*	Two of 2 CR	None	54

Virus	T-cell activator or capture	Patients	Antiviral effects	GVHD	Reference
IFN−γ capture
EBV	Peptides derived from 11 EBV antigens	6	CR in 3 of 6 patients	None	49
EBV	EBNA-1 protein	10	CR in 7 of 10 patients	One grade 2 skin GVHD	23
CMV	CMV-pp65 protein	18	PR or complete response in 15 of 18	One possible GVHD	22
CMV	Recombinant pp65 or pool of overlapping CMV-pp65 peptides	18	Eleven of 11 cleared disease	Five grade 1; 2 grade 2; 1 grade 3 acute GVHD	38
CMV	Two CMV-pp65 peptides	6	Six of 6 cleared CMV viremia	None	50
ADV	ADV antigen type C	9	Five of 6 evaluable had complete response or PR	One exacerbation of GVHD	37
ADV	ADV hexon protein	30	Twenty-one of 30 responded	Two with grade 1 GVHD	51
Multimer selection
CMV	Peptides from CMV-pp65 or IE-1	9	Eight of 9 cleared CMV	Two with grade 1 or 2 GVHD	52
CMV	Peptides from CMV-pp65	2	Two of 2 CR	None	53
CMV	NLV-containing HLA-A02 pentamers	2*	Two of 2 CR	None	54